Nisa Investment Advisors
IRLA

Nisa Investment Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Nisa Investment Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16
Closed -$20K – 2485
2022
Q1 		$20K Buy
16
+14
+700% +$19.1K ﹤0.01% 2052
2021
Q4 		$2K Hold
2
– – ﹤0.01% 2128
2021
Q3 		$27K Buy
+2
New +$31.8K ﹤0.01% 2038
2021
Q1 		– Sell
-1
Closed -$6K – 2313
2020
Q4 		$6K Buy
+1
New +$8.86K ﹤0.01% 2260

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Nisa Investment Advisors's IRLA Position: Q2 2022 in Review

Nisa Investment Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 16 shares — an estimated $20K sold.

Nisa Investment Advisors first reported a position in IRLA in Q4 2020 and held it in 4 quarters. The position peaked at $27K in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

  • Nisa Investment Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nisa Investment Advisors sold 16 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $20K.
  • Nisa Investment Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Nisa Investment Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $27K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Nisa Investment Advisors's 13F filing for Q2 2022, filed 3 Aug 2022.